EUVIMEDEUVIMED entdecken
Leserbrief

Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab

Shabnam Afzal, Deena Fayyad, Aamir N Hussain

Dermatitis® · 15.06.2026

DOI: 10.1177/17103568261461069 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Dermatitis®, online erschienen am 15.06.2026. Verfasst von Shabnam Afzal und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of California Davis School of Medicine, Sacramento, California, USA. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • University of California Davis School of Medicine, Sacramento, California, USA.
  • University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Anne Arundel Dermatology, McLean, Virginia, USA.

Zitieren

APA

Afzal, S., Fayyad, D., & Hussain, A. N. (2026). Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab. Dermatitis®. https://doi.org/10.1177/17103568261461069

Vancouver

Afzal S, Fayyad D, Hussain AN. Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab. Dermatitis®. 2026. doi:10.1177/17103568261461069

BibTeX
@article{Afzal2026,
  author = {Afzal, Shabnam and Fayyad, Deena and Hussain, Aamir N},
  title = {Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab},
  journal = {Dermatitis®},
  year = {2026},
  doi = {10.1177/17103568261461069}
}
Kostenlos starten →